Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. executive Marcus Jewell has reported his initial equity holdings in the company. As Global Chief Revenue Officer, he directly holds 453,142 Ordinary Shares. This amount includes several blocks of restricted share units (RSUs) granted in 2023, 2025 and 2026, which vest in quarterly installments from May 2026 through February 2030.
He also holds stock options linked to 301,507 Ordinary Shares at an exercise price of $7.96 per share, expiring on November 14, 2033. Of these options, 169,599 are already vested and exercisable, while 18,844 additional options vest on May 15, 2026 and then every three months through November 15, 2027.
Cellebrite DI Ltd. executive Holly B. Windham has filed an initial statement of beneficial ownership, reporting direct holdings of 95,328 Ordinary Shares. These are represented entirely by restricted share units granted on two dates.
One grant covers 47,938 RSUs awarded on November 5, 2025, with 11,986 vesting on the first anniversary and 2,996 vesting every three months through November 5, 2029. A second grant covers 47,390 RSUs awarded on February 10, 2026, with 11,858 vesting on the first anniversary and 2,961 vesting every three months through February 10, 2030. Each RSU converts into one Ordinary Share upon settlement, so the filing describes current and future equity-based compensation rather than a new market transaction.
Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee filed a Form 3 reporting his initial equity holdings in the company. He directly holds 147,933 Ordinary Shares, including restricted share units and performance share units granted in 2024, 2025 and 2026 with multi‑year vesting schedules.
He also holds stock options over 86,730 Ordinary Shares at an exercise price of $11.53 per share, expiring on May 19, 2034. Of these options, 37,950 are already vested and exercisable, with an additional 5,420 vesting on May 20, 2026 and every three months thereafter through May 20, 2028.
Cellebrite DI Ltd. officer David Barter filed an initial ownership report showing a compensatory equity position in the company. He beneficially holds 375,953 restricted share units (RSUs), each representing one ordinary share. These RSUs were granted on July 7, 2025 and vest over time through July 7, 2029, starting with 93,989 units on the first anniversary and 23,497 units every three months thereafter.
Cellebrite DI Ltd. director Dafna Gruber filed an initial ownership report showing beneficial ownership of 27,919 Ordinary Shares. This total includes 10,601 Ordinary Shares represented by restricted share units granted on September 17, 2025 that vest on September 17, 2026, with each RSU settling into one Ordinary Share.
Cellebrite DI Ltd. Chief Technology Officer Wade Christopher Michael has reported his initial ownership of 610,453 ordinary shares. This Form 3 filing is a disclosure of his existing stake rather than a new trade.
The total includes 31,593 ordinary shares represented by restricted share units granted on February 10, 2026. Of these RSUs, 7,905 are scheduled to vest on the first anniversary of the grant date, and 1,974 vest every three months thereafter through February 10, 2030. Each RSU converts into one ordinary share when it settles, tying part of his compensation directly to future company performance.
Cellebrite DI Ltd. director Brandon Van Buren filed an initial Form 3 reporting his ownership in the company. He reports beneficial ownership of 35,554 Ordinary Shares. This total includes 10,601 Ordinary Shares represented by restricted share units granted on September 17, 2025 that vest on September 17, 2026.
Cellebrite DI Ltd. director Adam Clammer filed an initial ownership report showing his holdings of ordinary shares. He holds 71,396 shares directly, including 10,601 time-based RSUs that vest on September 17, 2026. Indirectly, he reports 13,861,007 shares held by TWC Tech Holdings II, LLC and 375,000 shares each held by a Long Term Trust and a Joint Revocable Trust, with 1,500,000 shares subject to transfer restrictions tied to performance-based vesting conditions. Clammer states he may be deemed to share beneficial ownership of certain securities but disclaims beneficial ownership beyond his pecuniary interest.
Cellebrite DI Ltd. files its annual Form 20-F as a leading provider of AI‑powered digital investigative and intelligence software and services for lawfully sanctioned investigations worldwide. The company’s ordinary shares trade on the Nasdaq Global Market.
Cellebrite reports strong expansion, with revenue rising from $271 million in 2022 to $476 million in 2025 and headcount increasing from 1,005 to 1,285 employees over the same period. As of February 23, 2026, 249,439,817 ordinary shares were outstanding. The filing emphasizes that more than 90% of revenue comes from government and public safety agencies and outlines extensive risks, including technology change, AI use and regulation, cybersecurity, reliance on third‑party technology, geopolitical instability, complex U.S. government contracting and CFIUS and FOCI mitigation obligations tied to the CyTech and Corellium acquisitions.
CLBT affiliate filed a Form 144 proposing the sale of 4,517 common shares originally issued as Restricted Stock Units on 02/20/2026. The filer reported two recent dispositions in the past three months: 2,609 shares sold on 02/23/2026 for $34,334.44 and 1,165 shares sold on 02/12/2026 for $16,612.90.